CNS 2021 poster: Reductions in oculogyric crisis duration and frequency in children with aromatic L-amino acid decarboxylase (AADC) deficiency treated with eladocagene exuparvovec gene therapy: Results from 3 clinical trials
Change in the duration and frequency of oculogyric crises (OGC) in children with AADC deficiency following treatment with eladocagene exuparvovec, an investigational gene therapy, are presented in this poster from the 2021 CNS Annual Meeting
The role of intraputaminal infusion of eladocagene exuparvovec as a gene therapy for the treatment of AADC deficiency in children is presented
The efficacy of eladocagene exuparvovec on the following primary endpoints is investigated: Duration (hours/week) of OGC episodes; Frequency (episodes/week) of OGC episodes; Percentage of time spent experiencing OGC episodes
Treatment emergent adverse events with eladocagene exuparvovec are also described
Eladocagene exuparvovec is an investigational gene therapy product currently being developed by PTC Therapeutics for the treatment of patients with deficiency of a protein called AADC. Eladocagene exuparvovec does not currently have a marketing authorization for the treatment of AADC deficiency.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-AADC-2100520 I February 2022
Sign in or register to access exclusive content on this site
Some cookies are essential, others help us improve your experience by providing insights into how the website is used. Select one or more of the cookie types listed below, and then save your preferences. Refer to our Cookies Statement for more information.
Performance cookies, which help us measure the website’s performance and improve your experience. In using performance cookies we do not store any personal data, and only use the information collected through these cookies in aggregated and anonymised form.